Biotin [58-85-5]

Référence HY-B0511-1g

Conditionnement : 1g

Marque : MedChemExpress


Description

Biotin, vitamin B7 and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids[1][2][3].

IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
ES-2 IC50
>100 μM
Compound: Biotin
Antiproliferative activity against human ES2 cells
Antiproliferative activity against human ES2 cells
[PMID: 38716896]
HEK-293T IC50
>100 μM
Compound: Biotin
Antiproliferative activity against HEK293T
Antiproliferative activity against HEK293T
[PMID: 38716896]
OVCAR-3 IC50
>100 μM
Compound: Biotin
Antiproliferative activity against human OVCAR-3 cells
Antiproliferative activity against human OVCAR-3 cells
[PMID: 38716896]
In Vitro

Biotin exhibits higher affinity on breast cancer (T47D) cells over normal mammary epithelial (MCF-12A) cells, with Kms of 9.24 μM and 53.1 μM, respecetively[4].
Biotin (0.09-100 μM; 0-70 min) is dose-dependently uptake by T47D cells with Vmax of 27.34 pmol/mg protein/min[4].
Biotin (1-1000 nM; 24 h) exerts function in the recovery of 7β-OHC (50 µM)-induced cell death and reduces cell adhesion[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[5]

Cell Line: Murine oligodendrocyte 158N cells
Concentration: 1, 10, 100, 1000 nM
Incubation Time: 24 hours
Result: Showed cytoprotective effects and prevents 7β-hydroxycholesterol-induced disruption of redox status.
Improved attenuation of oxidative stress, mitochondrial dysfunction, lipid metabolism alteration.
In Vivo

Biotin (15 mg/kg/d; p.o.; 12 d) improves nephrotoxicity in streptozotocin-induced (150 mg/kg; i.p.) diabetic mice[6].
Biotin (0.012 mg/kg/d; p.o.; 70 d) deficiency impaires the immune function of the head kidney, spleen and skin in fish with inadequate administration dose[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Streptozotocin-induced Diabetes type 1 in male Swiss albino mice (25±2 g)[6]
Dosage: 15 mg/kg/d
Administration: Oral gavage; 12 days
Result: Improved histopathological results, including distorted glomeruli, inflammatory cells, and giant macrophages, and diminished acroline reaction of oxidative damage.
Animal Model: Grass carp (117±0.5 g)[7]
Dosage: 0.012, 0.110, 0.214, 0.311, 0.427, and 0.518 mg/kg
Administration: Oral gavage; 70 days
Result: Reduced the activities of lysozyme (LZ) and acid phosphatase (ACP), decreased the contents of complement 3 (C3), C4 and immunoglobulin M (IgM).
Reduced the mRNA levels of anti-microbial substances.
Increased the mRNA levels of pro-inflammatory cytokines, tumour necrosis factor partially and reduced anti-inflammatory IL-4/13A, IL-10, IL-11 and TGF-β1 mRNA levels partially in association with target of rapamycin (TOR) signaling.
Masse moléculaire

244.31

Formule

C10H16N2O3S

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CCCC[C@@H]1SC[C@]([C@]1(20)N2)(20)NC2=O

Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (409.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0932 mL 20.4658 mL 40.9316 mL
5 mM 0.8186 mL 4.0932 mL 8.1863 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 1.96 mg/mL (8.02 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT